Whilst no data exist in this specific patient group, the clinical efficacy of daratumumab was recently proven in relapses of T-ALL or CD19/CD22-negative ALL following allogeneic stem cell transplantation [124]. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.